Cellular immunotherapy for cancer: Current concepts and clinical perspectives monitoring immune responses and clinical trials: Part II

Clinical Oncology

Volumn 16, Issue 6, 2004, Pages 395-404

  Spicer, J ^a   Quatan, N ^b   Plunkett, T ^a   Pandha, H ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; C REACTIVE PROTEIN; CANCER VACCINE; CANVAXIN; CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; FLUOROCHROME; GAMMA INTERFERON; GANGLIOSIDE GM2; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELACINE; MELANOMA VACCINE; MESSENGER RNA; NEOPTERIN; PEPTIDE DERIVATIVE; PHYCOERYTHRIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT VACCINE; T LYMPHOCYTE ANTIGEN; TETRAMER; TUMOR ANTIGEN; TUMOR MARKER; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA ONCOLYSATE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CELL ASSAY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEVER; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNE RESPONSE; INJECTION SITE; INJECTION SITE REACTION; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MELANOMA; METASTASIS; MONITORING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

EID: 4444358558     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2004.03.014     Document Type: Article

References (73)

1. Wirleitner B. Reider D. Ebner S. et al. Monocyte-derived dendritic cells release neopterin J Leukoc Biol 72 2002 1148-1153
2. Murr C. Widner B. Wirleitner B. Fuchs D. Neopterin as a marker for immune system activation Curr Drug Metab 3 2002 175-187
3. Lissoni P. Barni S. Ardizzoia A. Scardino E. Tancini G. Vigano M.G. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients J Biol Regul Homeost Agents 9 1995 21-23
4. Waksman B.H. Cellular hypersensitivity and immunity: conceptual changes in last decade Cell Immunol 42 1979 155-169
5. Poulter L.W. Seymour G.J. Duke O. Janossy G. Panayi G. Immunohistological analysis of delayed-type hypersensitivity in man Cell Immunol 74 1982 358-369
6. Baral R.N. Saha A. Chatterjee S.K. et al. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen Cancer Immunol Immunother 52 2003 317-327
7. Kokhaei P. Rezvany M.R. Virving L. et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL Leukemia 17 2003 894-899
8. Kobayashi K. Noguchi M. Itoh K. Harada M. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients Cancer Sci 94 2003 622-627
9. Lipton A. Ali S.M. Leitzel K. et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen J Clin Oncol 21 2003 1967-1972
10. Peterson A.C. Harlin H. Gajewski T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma J Clin Oncol 21 2003 2342-2348
11. Bettinotti M.P. Panelli M.C. Ruppe E. et al. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178 Int J Cancer 105 2003 210-216
12. Hulett H.R. Bonner W.A. Barrett J. Herzenberg L.A. Cell sorting: automated separation of mammalian cells as a function of intracellular fluorescence Science 166 1969 747-749
13. Altman J.D. Moss P.A. Goulder P.J. et al. Phenotypic analysis of antigen-specific T lymphocytes Science 274 1996 94-96
14. Glazyrin A.L. Kan-Mitchell J. Mitchell M.L. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells Cancer Immunol Immunother 52 2003 171-178
15. Smith J.W. 2nd Walker E.B. Fox B.A. Haley D. Wisner K.P. Doran T. et al Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses J Clin Oncol 21 2003 1562-1573
16. Zajac P. Oertli D. Marti W. et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients Hum Gene Ther 14 2003 1497-1510
17. Si M.S. Ji P. Tromberg B.J. et al. Farnesyltransferase inhibition: a novel method of immunomodulation Int Immunopharmacol 3 2003 475-483
18. Hersey P. Murray E. Grace J. McCarthy W.H. Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma Pathology 17 1985 385-391
19. McGovern V. Spontaneous regression of malignant melanoma In: Blaustein A. (Ed.) Melanoma: histological diagnosis and prognosis 1982 18-47 Raven Press New York
20. Chan A.D. Morton D.L. Active immunotherapy with allogeneic tumor cell vaccines: present status Semin Oncol 25 1998 611-622
21. Berd D. Cancer vaccines: reborn or just recycled? Semin Oncol 25 1998 605-610
22. Berd D. Maguire H.C. Bloome E. Clark C. Medley W. Mastrangelo M.J. Regression of lung metastases after immunotherapy with autologous DNP modified melanoma vaccine Proc Am Soc Clin Oncol 17 1998 434a
23. Berd D. Maguire H.C. Jr. Schuchter L.M. et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases J Clin Oncol 15 1997 2359-2370
24. Belli F. Testori A. Rivoltini L. et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings J Clin Oncol 20 2002 4169-4180
25. Bystryn J.C. Oratz R. Shapiro R.L. et al. Phase III double-blind trial of a shed polyvalent melanoma vaccine in stage III melanoma Proc Am Soc Clin Oncol 17 1998 434
26. Wallack M.K. Sivanandham M. Balch C.M. et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial J Am Coll Surg 187 1998 69-77
27. Mitchell M.S. Perspective on allogeneic melanoma lysates in active specific immunotherapy Semin Oncol 25 1998 623-635
28. Sondak V.K. Liu P.Y. Tuthill R.J. et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group J Clin Oncol 20 2002 2058-2066
29. Hersey P. Coates A.S. McCarthy W.H. et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial J Clin Oncol 20 2002 4181-4190
30. Sosman J.A. Unger J.M. Liu P.Y. et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome J Clin Oncol 20 2002 2067-2075
31. Morton D.L. Foshag L.J. Hoon D.S. et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 216 1992 463-482
32. Chung M.H. Gupta R.K. Hsueh E. et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy J Clin Oncol 21 2003 313-319
33. DiFronzo L.A. Gupta R.K. Essner R. et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine J Clin Oncol 20 2002 3242-3248
34. Hsueh E.C. Gupta R.K. Qi K. Morton D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine J Clin Oncol 16 1998 2913-2920
35. Hsueh E.C. Essner R. Foshag L.J. et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine J Clin Oncol 20 2002 4549-4554
36. Hsueh EC, Foshag L, Essner R, Stern S, Morton DL. A new paradigm for the management of metastatic melanoma. In: Society of surgical oncology annual meeting. New Orleans: 2000.
37. Restifo N.P. Rosenberg S.A. Developing recombinant and synthetic vaccines for the treatment of melanoma Curr Opin Oncol 11 1999 50-57
38. Livingston P.O. Wong G.Y. Adluri S. et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036-1044
39. Eggermont A.M. Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma Eur J Cancer 34 suppl 3 1998 22-26
40. Kirkwood J.M. Ibrahim J.G. Sosman J.A. et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 19 2001 2370-2380
41. Kefford R.F. Adjuvant therapy of cutaneous melanoma: the interferon debate Ann Oncol 14 2003 358-365
42. Nestle F.O. Alijagic S. Gilliet M. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments] Nat Med 4 1998 328-332
43. Thurner B. Haendle I. Roder C. et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J Exp Med 190 1999 1669-1678
44. Rosenberg S.A. Yang J.C. Schwartzentruber D.J. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 1998 321-327
45. Palmer K. Moore J. Everard M. et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma Hum Gene Ther 10 1999 1261-1268
46. Young R.C. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? N Engl J Med 338 1998 1305-1306
47. Rosenberg S.A. Yang J.C. White D.E. Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response Ann Surg 228 1998 307-319
48. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators Lancet 353 1999 14-17
49. Gaugler B. Brouwenstijn N. Vantomme V. et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma Immunogenetics 44 1996 323-330
50. Simons J.W. Jaffee E.M. Weber C.E. et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res 57 1997 1537-1546
51. Repmann R. Goldschmidt A.J. Richter A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis Anticancer Res 23 2003 969-974
52. Jocham D. Richter A. Hoffman L. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 2004 594-599
53. Schwaab T. Heaney J.A. Schned A.R. et al. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters J Urol 163 2000 1322-1327
54. Nelson W.G. Simons J.W. Mikhak B. et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies Cancer Chemother Pharmacol 46 suppl 2000 67-72
55. Holtl L. Zelle-Rieser C. Gander H. et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells Clin Cancer Res 8 2002 3369-3376
56. Marten A. Flieger D. Renoth S. et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial Cancer Immunol Immunother 51 2002 637-644
57. Hrouda D. Baban B. Dunsmuir W.D. Kirby R.S. Dalgleish A.G. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172) Br J Urol 82 1998 568-573
58. Eaton J.D. Perry M.J. Nicholson S. et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer BJU Int 89 2002 19-26
59. Simons J.W. Mikhak B. Chang J.F. et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer Cancer Res 59 1999 5160-5168
60. Heiser A. Coleman D. Dannull J. et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors J Clin Invest 109 2002 409-417
61. Small E.J. Fratesi P. Reese D.M. et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 2000 3894-3903
62. Hsu F.J. Caspar C.B. Czerwinski D. et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial Blood 89 1997 3129-3135
63. Bendandi M. Gocke C.D. Kobrin C.B. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma Nat Med 5 1999 1171-1177
64. Timmerman J.M. Czerwinski D.K. Davis T.A. et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood 99 2002 1517-1526
65. Riethmuller G. Holz E. Schlimok G. et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial J Clin Oncol 16 1998 1788-1794
66. Vermorken J.B. Claessen A.M. van Tinteren H. et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 353 1999 345-350
67. Harris J.E. Ryan L. Hoover H.C. Jr. et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283 J Clin Oncol 18 2000 148-157
68. Habal N. Gupta R.K. Bilchik A.J. et al. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer Ann Surg Oncol 8 2001 389-401
69. Koutsky L.A. Ault K.A. Wheeler C.M. et al. A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 347 2002 1645-1651
70. Borysiewicz L.K. Fiander A. Nimako M. et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer Lancet 347 1996 1523-1527
71. Kaufmann A.M. Stern P.L. Rankin E.M. et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer Clin Cancer Res 8 2002 3676-3685
72. Davidson E.J. Kitchener H.C. Stern P.L. The use of vaccines in the prevention and treatment of cervical cancer Clin Oncol 14 2002 193-200
73. Morton D.L. Eilber F.R. Holmes E.C. Ramming K.P. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases Aust N Z J Surg 48 1 1978 Feb 49-52